Search
Meningococcal polysaccharide vaccine group A
go.drugbank.com/drugs/DB13889ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.
Mixtures: Mencevax Ac Pws Inj 2500mcg/vial, MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADETMagnesium citrate
go.drugbank.com/drugs/DB11110ApprovedInvestigational[L2831] It is also considered as an active ingredient in over-the-counter products.[L1113] … Magnesium citrate is a low volume and osmotic cathartic agent.
Mixtures: Min-tran TabIsotretinoin
go.drugbank.com/drugs/DB00982ApprovedInvestigational[L6574] Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. … Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.
Categories: Retinoids for Topical Use in AcnePanobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalThe approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted … Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma.
Synonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Cilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalTixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Acute Migraine
go.drugbank.com/conditions/DBCOND0043723Davamotecan pegadexamer
go.drugbank.com/drugs/DB05899InvestigationalEP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound [camptothecin].
Categories: Compounds used in a research, industrial, or household settingInfluenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14404ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer FertigspritzeNeisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen
go.drugbank.com/drugs/DB10284ApprovedInvestigationalIt is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily … Neisseria meningitidis serogroup B recombinant lp2086 a05 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused
Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML